91-105 of 937
ADAPT AF-DES: Antithrombotic Strategies Beyond 12 Months for Patients With AF Treated With Drug-Eluting-Stents
CardiologyADAPT AF-DES: Antithrombotic Strategies Beyond 12 Months for Patients With AF Treated With Drug-Eluting-Stents
Jung-Sun Kim, MD, PhD
OCEAN Trial at AHA 2025: Anticoagulation After AF Ablation in High-Risk Patients
CardiologyOCEAN Trial at AHA 2025: Anticoagulation After AF Ablation in High-Risk Patients
Atul Verma, MD
Primary Results of the VESALIUS-CV Trial: Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke
CardiologyPrimary Results of the VESALIUS-CV Trial: Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke
Erin Bohula, MD, DPhil
Real-World Impact of Evolocumab on MACE Reduction in ASCVD
CardiologyReal-World Impact of Evolocumab on MACE Reduction in ASCVD
Nihar R. Desai, MD, MPH
Global Burden of Stroke and Myocardial Infarction in Patients at High Risk of First MACE: Insights From the VESALIUS-REAL Study
CardiologyGlobal Burden of Stroke and Myocardial Infarction in Patients at High Risk of First MACE: Insights From the VESALIUS-REAL Study
Matthew Jay Budoff, MD
Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke: Primary Results of the VESALIUS-CV Trial
CardiologyEvolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke: Primary Results of the VESALIUS-CV Trial
Lawrence Leiter
- advertisement
Finerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
NephrologyFinerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
prof. Hiddo Heerspink
Implications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
NephrologyImplications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
Richard E. Pratley, MD
New Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
NephrologyNew Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
prof. Hiddo Heerspink
The Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial
NephrologyThe Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial
Rajiv Agarwal, MBBS, MD, FASN, BRCU
PREVENT vs PCE: Refining ASCVD Risk Prediction in Statin-Treated Populations
Heart MattersPREVENT vs PCE: Refining ASCVD Risk Prediction in Statin-Treated Populations
The LDL-C Gap in Statin-Treated Patients: A Population-Level Problem with Economic Consequences
Heart MattersThe LDL-C Gap in Statin-Treated Patients: A Population-Level Problem with Economic Consequences
- advertisement
Reframing Monotherapy and Combination Strategies for Hyperlipidemia
Heart MattersReframing Monotherapy and Combination Strategies for Hyperlipidemia
Understanding Preload Deficiency in SLE: A New Look at Fatigue and Exercise Intolerance
Living RheumUnderstanding Preload Deficiency in SLE: A New Look at Fatigue and Exercise Intolerance
Ryan Quigley
Luigi Adamo, MD, PhD
Andrea Fava, MD
Managing Genotype-Positive Patients in Hereditary ATTR-CM
On the Frontlines of ATTR-CMManaging Genotype-Positive Patients in Hereditary ATTR-CM
Shelina Ramnarine, PhD
Naveen L. Pereira, MD
